Friday, December 5, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Nel ASA Faces Severe Headwinds as Order Intake Plummets

Robert Sasse by Robert Sasse
October 21, 2025
in Analysis, Earnings, European Markets, Hydrogen, Turnaround
0
Nel ASA Stock
0
SHARES
20
VIEWS
Share on FacebookShare on Twitter

The hydrogen sector specialist Nel ASA is confronting substantial operational challenges, with recent quarterly results revealing significant deterioration across key performance metrics. The company’s latest financial disclosures paint a concerning picture for the electrolyzer manufacturer’s near-term prospects.

Financial Performance Shows Marked Decline

During the second quarter of 2025, Nel ASA reported revenues of just 174 million Norwegian Kronen, representing a stark 48 percent decline compared to the same period last year. The company’s operational losses widened slightly, with EBITDA standing at negative 86 million NOK. These figures underscore the substantial operational headwinds the company currently faces, highlighting the gap between the renewable energy sector’s long-term potential and immediate implementation challenges.

Order Collapse Reaches Critical Levels

The most alarming development emerges from the company’s order pipeline. New order intake collapsed by 74 percent year-over-year to a mere 71 million Norwegian Kronen. The order backlog, a crucial indicator of future revenue potential, contracted significantly by 40 percent to 1,249 million Kronen.

This downturn was particularly severe within the alkaline electrolyzer segment, where orders plummeted by 94 percent. While the PEM segment demonstrated relative stability, it proved insufficient to counterbalance the overwhelming decline across the business. This pattern suggests deep-seated market uncertainty and hesitation among potential clients.

Should investors sell immediately? Or is it worth buying Nel ASA?

Industry-Wide Pressures Intensify

Nel ASA’s struggles occur against a backdrop of sector-wide difficulties. The entire hydrogen industry is experiencing protracted delays in final investment decisions for major projects. This widespread investment caution represents a primary driver behind the deteriorating order figures.

The company suffered an additional setback with energy firm Statkraft canceling a significant 40-megawatt electrolyzer contract. Market conditions currently present little room for optimistic interpretation, as demonstrated by these key metrics:

  • Q2 2025 Revenue: 48% year-over-year decrease
  • Q2 2025 Order Intake: 74% year-over-year decline
  • Order Backlog: 40% year-over-year reduction
  • Q2 2025 EBITDA: Negative 86 million NOK

Despite these challenging conditions, a recent order from H2 Energy in early October provided a minor positive development. However, this single contract does little to alter the prevailing negative trajectory. The company’s performance continues to reflect a clear downward trend, with recovery prospects remaining uncertain amid current market dynamics.

Ad

Nel ASA Stock: Buy or Sell?! New Nel ASA Analysis from December 5 delivers the answer:

The latest Nel ASA figures speak for themselves: Urgent action needed for Nel ASA investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 5.

Nel ASA: Buy or sell? Read more here...

Tags: Nel ASA
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Intellia Therapeutics Stock
Analysis

Intellia Therapeutics Shares Remain Under Pressure as Regulatory Concerns Linger

December 5, 2025
Procter & Gamble Stock
Consumer & Luxury

P&G Shares Under Pressure as Finance Chief Highlights U.S. Demand Weakness

December 5, 2025
Healwell AI Stock
AI & Quantum Computing

Healwell AI Shares Show Tentative Signs of Finding a Floor

December 5, 2025
Next Post
Vulcan Energy Resources Stock

Strategic Partnership with Glencore Marks Turning Point for Vulcan Energy

Infineon Stock

Infineon Shares: The Struggle for Market Momentum

Commerzbank Stock

Commerzbank Unleashes Billion-Euro Share Buyback Program

Recommended

Standard Lithium Stock

Standard Lithium Reaches Critical Milestone in Arkansas Venture

1 month ago
BioNTech Stock

BioNTech Shares Plunge as Financial Performance Raises Concerns

2 months ago
Fannie Mae Stock

Fannie Mae Shares Face Intensifying Pressure Amid Leadership Overhaul

4 weeks ago
Canaan Stock

Canaan Shares Face Critical Test Amid Expansion Moves

1 month ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Setback for European Lithium as Key Austrian Permit Overturned

ServiceNow Pursues Dual-Pronged Strategy with Major Acquisition and Stock Split

Institutional Investors Drive Significant Accumulation in ADT Shares

AvePoint’s Robust Performance and Strategic Edge in AI Governance

Coeur Mining Stock Faces Conflicting Market Pressures

CureVac Nears Final Chapter with BioNTech Acquisition and Index Removal

Trending

Intellia Therapeutics Stock
Analysis

Intellia Therapeutics Shares Remain Under Pressure as Regulatory Concerns Linger

by Andreas Sommer
December 5, 2025
0

Shares of genome-editing company Intellia Therapeutics closed the trading week in negative territory, continuing a period of...

Procter & Gamble Stock

P&G Shares Under Pressure as Finance Chief Highlights U.S. Demand Weakness

December 5, 2025
Healwell AI Stock

Healwell AI Shares Show Tentative Signs of Finding a Floor

December 5, 2025
European Lithium Stock

Setback for European Lithium as Key Austrian Permit Overturned

December 5, 2025
ServiceNow Stock

ServiceNow Pursues Dual-Pronged Strategy with Major Acquisition and Stock Split

December 5, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Intellia Therapeutics Shares Remain Under Pressure as Regulatory Concerns Linger
  • P&G Shares Under Pressure as Finance Chief Highlights U.S. Demand Weakness
  • Healwell AI Shares Show Tentative Signs of Finding a Floor

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com